Means and Methods for Diagnosing Heart Failure in a Subject

• US 20120286157A1
• Filed: 01/28/2011
• Published: 11/15/2012
• Est. Priority Date: 01/29/2010
• Status: Active Grant

• Current Assignee: Metanomics Gmbh (BASF SE), Ruprecht-Karls-Universitã¤T Heidelberg
• Original Assignee: Metanomics Gmbh (BASF SE), Ruprecht-Karls-Universitã¤T Heidelberg
• Inventors: Fuhrmann, Jens, Reszka, Regina, Kastler, Jürgen, Busch, Kristina, Leibold, Edgar, Katus, Hugo, Frey, Norbert, Wolf, Johanna, Weis, Tanja
• Granted Patent: US 9,285,378 B2
• Time in Patent Office: Days
• US Class Current: 250/282
• CPC Class Codes: A61B 5/02 Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: G01N 2570/00 Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/48 Biological material, e.g. blood, urine G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence; Haemocytometers counting blood corpuscules distributed over a surface by scanning the surface G06M11/02
• CPC Class Codes: G01N 33/64 involving ketones
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject, a method for identifying whether a subject is in need for a therapy of heart failure or a method for determining whether a heart failure therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Claims

1-14. -14. (canceled)

15. A method for diagnosing heart failure in a subject comprising the steps of:

a) determining in a sample of a subject suspected to suffer from heart failure the amount of at least one biomarker selected from the group consisting of biomarkers listed in Table 1a to c, 3, 4a to c or 6;

b) comparing the amount of said at least one biomarker to a reference, whereby heart failure is to be diagnosed.

16. The method of claim 15, wherein the heart failure is heart failure according to NYHA class I and the at least one biomarker is selected from Table 4a to c or 6.

17. The method of claim 15, wherein the sample of the subject has been obtained under resting and wherein the at least one biomarker is selected from Table 1a to c or 4a to c.

18. The method of claim 15, wherein the sample of the subject has been obtained under exercise and wherein the at least one biomarker is selected from Table 3 or 6.

19. The method of claim 15, wherein the reference is derived from a subject or group of subjects known not to suffer from heart failure or a calculated reference.

20. The method of claim 19, wherein a difference between the reference and the amount of the at least one biomarker is indicative for heart failure.

21. The method of claim 15, wherein the reference is derived from a subject or group of subjects known to suffer from heart failure.

22. The method of claim 21, wherein a reference being identical with the at least one biomarker is indicative for heart failure.

23. The method of claim 15, wherein the heart failure is congestive heart failure.

24. The method of claim 15, wherein the subject suffers from dilated cardiomyopathy, ischemic cardiomyopathy, and/or hypertrophic cardiomyopathy.

25. A method for identifying whether a subject is in need for a therapy of heart failure comprising the steps of the method of claim 15, and a further step of identifying a subject in need for therapy if heart failure is diagnosed.

26. A method for determining whether a therapy against heart failure is successful in a subject comprising the steps of the method of claim 15, and a further step of determining whether a therapy is successful if no heart failure is diagnosed.

27. A method for diagnosing heart failure in a subject comprising the steps of:

a) determining in a first and a second sample of a subject suspected to suffer from heart failure the amount of at least one biomarker selected from the group consisting of biomarkers listed in Table 2 or 5, wherein said first sample has been obtained at rest and said second sample has been obtained under exercise;

b) calculating a ratio of the amount of the at least one biomarker determined in the first and the second sample; and

c) comparing the calculated ratio to a reference, whereby heart failure is to be diagnosed.

28. The method of claim 27, wherein the heart failure is heart failure according to NYHA class I and the at least one biomarker is selected from Table 5.

29. The method of claim 27, wherein the reference is derived from a subject or group of subjects known not to suffer from heart failure or a calculated reference.

30. The method of claim 29, wherein a difference between the reference and the amount of the at least one biomarker is indicative for heart failure.

31. The method of claim 27, wherein the reference is derived from a subject or group of subjects known to suffer from heart failure.

32. The method of claim 31, wherein a reference being identical with the at least one biomarker is indicative for heart failure.

33. The method of claim 27, wherein the heart failure is congestive heart failure.

34. The method of claim 27, wherein the subject suffers from dilated cardiomyopathy, ischemic cardiomyopathy, and/or hypertrophic cardiomyopathy.

35. A method for identifying whether a subject is in need for a therapy of heart failure comprising the steps of the method of claim 27, and a further step of identifying a subject in need for therapy if heart failure is diagnosed.

36. A method for determining whether a therapy against heart failure is successful in a subject comprising the steps of the method of claim 27, and a further step of determining whether a therapy is successful if no heart failure is diagnosed.